The core risk is time-to-repeatable-commercial-outcomes: IonQ must turn roadmap progress and acquisitions into standardized, high-uptime products with clear buyer ROI. If not, revenue stays lumpy, cash funds long R&D cycles, and the stock can grind via
dilution and
multiple compression. Secondary risks are competitive convergence (classical AI/HPC reduces quantum’s edge), government procurement delays, and credibility risk if benchmarks and deployments don’t translate into durable customer retention.